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The topographic features at the cell–material biointerface are critical for
cellular sensing of the extracellular environment (ECM) and have gradually
been recognized as key factors that regulate cell adhesion behavior. Herein, a
well-defined nanostructured biointerface is fabricated via a new generation of
mussel-inspired polymer coating to mimic the native ECM structures. Upon
the bioinert background presence and biospecific ligands conjugation, the
affinity of cancer cells to the resulting biofunctional surfaces, which integrate
topographic features and biochemical cues, is greatly strengthened. Both the
conjugated bioligand density, filopodia formation, and focal adhesion
expression are significantly enhanced by the surficial nano-features with an
optimized size-scale. Thus, this nanostructured biointerface exhibits high
capture efficiency for circulating tumor cells (CTCs) with high sensitivity, high
biospecificity, and high purity. Benefiting from the unique bioligands
conjugation chemistry herein, the captured cancer cells can be responsively
detached from the biointerfaces without damage for downstream analysis.
The present biofunctional nanostructured interfaces offer a good solution to
address current challenges to efficiently isolate rare CTCs from blood samples
for earlier cancer diagnosis.
1. Introduction
It is well known that the extracellular matrix is a complex fibrous
network with micro-/nano hierarchical features (ranging from
260 to 410 nm).[1] Cell growth and functions are tightly associated
with the cellular interactions at the cell-ECM biointerface.[2] Over
the past two decades, a series of nano/microstructured bioin-
terfaces with the abilities to control cell adhesion/detachment
and enhance cellular sensing to external signals have been
developed.[2,3] These biointerfaces provide possibilities to mimic
the natural nanostructure of ECMs and exhibit potential ap-
plications in tissue engineering and regenerative medicine.
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The larger surface area and unique interac-
tions between nanostructured biointerfaces
and cells facilitate firm cellular attachment
and exhibit great advantages in the isola-
tion and detection of rare cells, for exam-
ple, the CTCs.[4] CTCs are cancer cells that
detach from primary tumors or metastatic
sites and circulate in the peripheral blood
as the cellular origin of metastasis.[5] Clin-
ical researches indicated that the levels
of CTCs in metastatic cancer patients
are a predictor of survival.[6] Cytogenetic
evidence also matched aneusomic patterns
between CTCs and those from the pri-
mary tumor.[7] Enumeration and isolation
of CTCs from patients’ blood can provide in-
sight into blood-borne metastasis, monitor
disease progression, and help to guide the
therapeutic outcomes of cancer.[8] There-
fore, technologies that can capture and de-
tect CTCs directly from the patient’s blood
are highly desired from a clinical point of
view for early cancer diagnosis. However,
the concentration of CTCs in a patient’s
blood circulatory system is ultra-low, usually a few to hundreds
per milliliter, therefore the isolation of CTCs from a patient’s
blood with high efficiency and purity is a big challenge.[9]
In order to detect and isolate these rare CTCs, multiple isola-
tion methods, for example, microfluidic devices, immunomag-
netic beads, and microfilter devices, have been developed by uti-
lizing the differences among cellular physical properties or diver-
sity of surface biomarkers of cancer cells.[10–13] Among them, the
methods based on affinity interaction between the bioligands at
the interfaces and the biomarkers on cancer cell membrane yield
higher efficiency and good specificity in contrast to mechanical
and electrical sorting technique.[14] But it is still difficult to isolate
the CTCs with higher purity and viability.[15] Recently, increas-
ing evidence indicates that biomimetic micro/nano topographic
features at the cell–material interface could greatly improve the
CTCs capture efficiency from patient blood.[16–20] Compared to a
flatter surface, the nanostructure features at the interface would
provide more surface area for the functionalization of antibodies
and/or aptamers, suitable sites for cancer cell trapping, as well
as further lowering the rolling velocity of cells.[15] Further results
also demonstrate that the nanostructured features may induce
the formation of pseudopodia on the nanostructured surface[21]
and improve cell–material surface adhesion force,[22] which fur-
ther increases the affinity between cancer cells and nanostruc-
tured substrates. Thus, more and more attention has been paid to
developing functionalized structured biointerfaces, for example,
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Scheme 1. Nanostructured multivalent biointerfaces for specific CTCs adhesion/isolation and responsively release based on mussel-inspired polymer
coating and the unique dynamic cis-diols-boronic ester chemistry (Mfp-5: mussel foot proteins-5, mPG: mussel-inspired linear polyglycerol, hPG-Cat:
5% catecholic hPG).
the integrated NanoVelcro system,[18,23–25] for rare CTCs capture
even if it generates another technological challenge to fabricate
those nano/micro hierarchical substrates.[13,26]
While higher nonspecific proteins and cells (white blood
cell) binding was also consequently observed on the rough
nanostructured surfaces in the absence of specific bioligand[27]
and antifouling background.[28] Nevertheless, the exact relation-
ship between cancer cell capture and the surface roughness or
topography of the biointerface has yet to be fully understood.
It is noted that different cancer cell lines may show diverse
preferred surface features and display dissimilar responsiveness
on the same nanostructured surface.[29] Furthermore, to carry
out cell proliferation and downstream analysis, the captured
CTCs should be pure enough and able to further detach from
the isolation platform with required viability. But the release of
the captured cells from the devices possibly causes cell damages
and impedes further insights into the biology of CTCs by usual
enzymatic and mechanical lift-off methods.[30] Thus, responsive
linker chemistry between isolation devices and CTCs specific
biomarkers is necessary to enable the controllable releasing of
the captured cells with minimal damages.
Herein, we presented an advanced biointerface that integrates
the biospecific affinity interaction and well-defined topographical
features for cancer cell isolation. A mussel-inspired coating poly-
mer was developed and used to fabricate the defined nanostruc-
tures on the biointerface via a simple dip-coating method with a
series of surface roughness that ranged from the nanometer to
the sub-micrometer scale (Scheme 1). Similar to our previous re-
ports about cell adhesion on rough surfaces,[31,32] the adhesion
and isolation of cancer cells on this nanostructured biointerface
exhibited a unique biphasic manner and an optimized rough-
ness was therefore found. To achieve a high capture specificity,
a bioinert hyperbranched polyglycerol (hPG) monolayer coating
was introduced onto the defined nanostructured biointerfaces,
which served as a strong antifouling background to resist the
nonspecific adhesion of proteins and blood cells (red blood cell,
white blood cell, platelets, etc.). On the other hand, the chemical
property of hPG was then explored to conjugate the epithelial-
cell adhesion molecule antibody (anti-EpCAM) onto the bioint-
erface via a revisable cis-diols-phenylboronic ester binding. No-
table evidence revealed that the presented nanostructure features
greatly promote the formation of cellular focal adhesion (FA) and
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filopodia in addition to the increase of surface area for antibody
conjugation. Thus, the resulting biointerfaces that combine
biospecific affinity interaction and surface nanostructures dis-
played an ultra-high capture efficiency for CTCs (>95%) with
high purity (>97%) and sensitivity, even for cells with low Ep-
CAM expression, for example, the MDA-MB-231 and A549 cells.
Moreover, upon exposure to a glycan molecule which has a higher
affinity to phenylboronic acid (PBA), that is, sorbitol,[33] the cap-
tured CTCs thus responsively release from the biointerfaces in a
short time without damage due to the competitive binding.
2. Results and Discussion
2.1. Mussel-Inspired Polymer Coating with Well-Defined Surficial
Features
To mimic the adhesion properties of mussel foot proteins, we
previously developed a mussel-inspired dendritic polyglycerol
(MI-dPG) coating polymer and versatile coating surfaces have
been successively fabricated via this building block.[31,32,34,35] Due
to the multivalent character of the dendritic polyglycerol, most
of the functional groups are exposed to the periphery.[34] The
crosslinking of the polymers is greatly accelerated but the result-
ing roughness and topographic features of the coating are far be-
yond control. To circumvent these limitations, a new generation
of mussel-inspired polyglycerol-based coating polymer (mPG)
with a linear polymer architecture was thus designed herein.
Compared with the dendritic architecture, the linear mPG has a
higher hydrodynamic radius and more entanglement conforma-
tion. Therefore, the reactivity of the heteromultivalent catechol-
and amine-groups on the polymer chain was decelerated and the
coating process was more controllable. The average molecular
weight of the mPG coating polymer is about 10 kDa, which is
similar to the mfp-5 (≈9 kDa).[36] While the functionality of the
catechol groups in the mPG polymer (70 mol%) is ≈2.5 times
higher than that in mpf-5 (27 mol%[37]) for rapid deposition. Un-
der basic conditions, the mPG underwent covalent crosslinking
and aggregated into nanoparticles, which were partially insolu-
ble in the coating solution (a mixture of methanol and water) and
were deposited onto the substrate (Figure 1a and Figure S1, Sup-
porting Information). Furthermore, the deposited particles pro-
gressively grew from nanoscale to microscale due to the consec-
utive Michael addition and/or dopa-quinone coupling (Figure 1b
and Figure S1, Supporting Information). With the increase of in-
cubation time at room temperature, the optical transmittance of
the resulting coating surface was progressively decreased (Fig-
ure 1c). While the thickness of mPG coating on the substrate con-
tinually increased with incubation and reached 340 nm after 4 h
and 760 nm after 24 h (Figure 1d), which is quite slow compared
with its dendritic analog[34] but much faster than the crosslink-
ing of dopamine under basic[38] and even oxidative conditions.[39]
The surface morphology and root mean square roughness (Rq) of
the resulting coating with different incubation time were further
characterized by atomic force microscopy (AFM) (Figure 1e,f).
mPG coating polymers adsorbed and gradually polymerized on
the substrate surface and generated well-defined topographical
features ranging from nanometers to micrometers with an in-
crease of coating time (Figure 1e). The surface roughness of the
resulting surfaces slowly increased from 56 nm (mPG1: 1-h incu-
bation) to 571 nm (mPG24: 24-h incubation) (Figure 1f), which
suggests that the catechol- and amine-groups inter/intra-polymer
coupling reaction are greatly affected by the polymer architecture.
Thus, the resulting coating process displays a more controllable
manner. Except for the difference in the surficial topographic fea-
tures, the resulting mPG coating surfaces maintain similar sur-
face chemical property (Figure S2, Supporting Information).
2.2. Cellular Response to Nanostructured mPG Surfaces
Displayed a Roughness Selective Manner
To investigate cell adhesion on the nanostructured surfaces, hu-
man breast cancer cells (MCF7) were seeded and cultured for
3 h. As shown in Figure 2a, the adhesion of MCF7 cells on
nanostructured mPG surfaces displayed an interesting biphasic
manner. The corresponding cell capture efficiency gradually in-
creased with the increase of surficial roughness and maximized
on mPG4 surfaces (Rq= 352 nm, capture efficiency>50%). Once
the surface roughness was above 352 nm, the topographic fea-
tures greatly restricted the cell adhesion, and thus the capture effi-
ciency was drastically reduced. This interesting cellular response
to nanostructured surficial features agrees with previous reports
on MCF7 cells[20] and mesenchymal stem cells (MSC)[31,32] but
the preferred roughness shifted to a lower region owing to the
smaller size of cancer cells.
Based on this special cell adhesion behavior of nanostructured
surfaces, we then asked whether these interfaces could be poten-
tially developed for the capture and isolation of rare CTCs from
blood samples. EpCAM (epithelial cell adhesion molecule) is a
typical CTCs biomarker, which is overexpressed in most adeno-
carcinoma CTCs but negative-expressed in normal blood cells.[40]
To obtain specific CTCs isolation, anti-EpCAM was then em-
ployed as a biospecific ligand and immobilized onto the nanos-
tructured mPG coating surface. As mentioned above, a strong
bioinert background is required to resist the interference of non-
specific proteins adsorption and blood cell (red blood cell, white
blood cell, and platelets) adhesion during CTCs isolation. There-
fore, a monolayer of antifouling hPG was introduced on the de-
fined nanostructured biointerfaces to guarantee the high capture
specificity and purity before bioligands conjugation. Catechol
functionalized hPG (5% functionality) quickly adsorbed onto the
mPG4 coating surface and then coupled with the amino and/or
quinone groups on the mPG4 surface to form a stable coating
in the basic buffer (Figure 2b). Based on the quantification of
QCM measurement, there are 88.4 ng cm−2 of hPG-Cat poly-
mers chemically anchored onto the mPG4 surface and generate
a 1.37 nm monolayer coating on the mPG4h nanostructured sur-
face. No obvious surface roughness change was observed after
hPG grafting (Figure S3, Supporting Information), which indi-
cated the mPG4 surface still maintains its nanostructured fea-
tures. In addition to the excellent antifouling properties, plenty
of cis-diol groups on the hPG polymer also offer an opportunity
to immobilize bioligands via the revisable cis-diol-phenylboronic
ester bonding. Thus, PBA-modified biotin was grafted onto the
hPG-mPG surfaces. The sharp decrease of frequency in the real-
time QCM curve indicated the rapid biotin-binding on the hPG-
mPG4 surface through the PBA/cis-diol esterification (Figure 2b).
Subsequently, biotinylated anti-EpCAM were conjugated onto
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Figure 1. Fabrication of nanostructured surfaces via the mussel-inspired coating polymer. a) One-step dip-coating method is used to prepared surfaces
with well-defined topographic features that result from the self-polymerization of mPG polymers under the basic condition and the deposition of formed
nanoparticles from mixing solution. b) Scanning electron microscope images of the resulting mPG coating surfaces with the variation of dip-coating
time. The scale bar indicates 10 µm. Time-dependent optical transmittance (c) and thickness (d) of the mPG coating surface. e) The surface morphology
and corresponding surface roughness (f) of mPG coating surfaces characterized by AFM. Scale bar indicates 10 µm. The mPG1, mPG2, mPG3, mPG4,
mPG6, and mPG24 indicate the resulting mPG coatings with 1, 2, 3, 4, 6, and 24 h dip-coating time respectively.
the coating surfaces via the biorthogonal avidin biolinker, which
could form the strongest non-covalent bonding with biotin.[41]
651.2 ng cm−2 of NeutrAvidin and 667.1 ng cm−2 of biotinylated
anti-EpCAM were stepwise conjugated onto mPG4 surfaces to
generate an anti-EpCAM functionalized biospecific nanostruc-
tured biointerfaces (Figure 2c).
Compared with the nanostructured mPG coating surface,
the adhesion of MCF7 cancer cells (EpCAM positive cell line)
on anti-EpCAM functionalized surfaces was significantly en-
hanced. The corresponding capture efficiency was greatly im-
proved for the surface with lower roughness and maximized
on the anti-EpCAM-mPG4 surface. More than 95% of spiked
cells from the serum-free medium were captured onto antibody-
functionalized mPG4 surface after 2 h of incubation (Figure 2d).
Thereafter, the capture efficiency on higher rough surfaces was
drastically reduced. Furthermore, no cells were obviously ob-
served on the hPG-mPG4 surfaces (Figure S4, Supporting In-
formation), indicating the nanostructured surfaces have an ex-
cellent bioinert background. To achieve the highly efficient cap-
ture of cancer cells, the nanostructured surfaces still required
the functionalization of biospecific ligands to recognize the
cells.
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Figure 2. Biospecific adhesion/capture of cancer cells on mPG surfaces with roughness selectivity manner. a) Cell capture on nanostructured mPG
surfaces (n = 20–30, 3 technical replicates). b) Real-time quartz crystal microbalance (QCM) frequency shift of the adsorption of antifouling hPG-Cat
polymers on mPG4 surface and the in situ immobilization of bioligands onto the resulting hPG-mPG4 surface via the unique diol-boronic ester bonding
between hPG and biotin-PBA. c) Real-time QCM frequency shift of the adsorption of NeutrAvidin and anti-EpCAM onto the biotin functionalized mPG4
surfaces via the bioorthogonal biotin-avidin interaction, respectively. d) Biospecific CTCs capture efficiency on the antibody (anti-EpCAM) functionalized
mPG coating surfaces (n = 30–35, 3 technical replicates).
2.3. High-performance Cancer Cell Capture on Biospecific
Nanostructured Surfaces
To assess the specifical cancer cell capture on the anti-EpCAM-
functionalized nanostructured interfaces, EpCAM-positive can-
cer cell line (MCF7[42]) was used as the model cell line, whereas
the EpCAM-negative cell line, that, GFP+-Hela cells,[43] and anti-
EpCAM functionalized smooth surfaces were employed as neg-
ative control cell line and negative control surface, respectively.
For microscopic observation, MCF7 cells were pre-stained with
a fluorescent tracker dye. All experimented cells were spiked in
serum-free RPMI-1640 culture medium with a concentration of
3000 cells mL−1. Unless otherwise specified, the nanostructured
biointerface in the following part was the antibody functional-
ized mPG4 surfaces with optimized antibody conjugation density
(Figure S5, Supporting Information). Benefiting from the nanos-
tructured features, cancer cell capture efficiency on both mPG4
surfaces with and without antibody functionalization was greatly
improved compared to the smooth control surfaces (Figure 3a,b).
More than 95% of spiked cells adhered to the anti-EpCAM-mPG4
surface whereas only 53% of the spiked cells were captured onto
the antibody functionalized smooth surfaces. Under the same
condition, less than 5% of EpCAM-negative HeLa cells were ob-
served on antibody functionalized mPG4 surfaces (Figure 3a,b).
The present anti-EpCAM displayed a good biospecific property
and remarkably reduced the nonspecific cell adhesion. Thus, only
EpCAM positive MCF7 cells were selectively captured by this
biointerface from the MCF7/HeLa mixture (Figure S6, Support-
ing Information). The hierarchical nanostructured features pro-
vide more surface area for cell interaction with the biointerfaces
and could further lower the rolling velocity of cells. Therefore,
spiked cancer cells tend to interact with the nanostructure fea-
tures and quickly adhered to the biointerface. The corresponding
capture efficiency on nanostructured mPG4 surface reached 90%
after 30 min and maximized to 95% after 1-h incubation, which
is about two or three times faster than many reported biointer-
faces for cancer cell capture.[44,45] For the smooth control surface,
the capture efficiency gradually reached 65% even after incuba-
tion for 3 h (Figure 3c). It suggests that the nanostructured fea-
tures on the surfaces could significantly facilitate the adhesion of
cancer cells on the biointerfaces with higher capture efficiency,
higher bioselectivity, and shorter detection time, potentially being
applied for fast cancer diagnosis. On the other hand, this signifi-
cant enhancement of biospecificity and bioselectivity may also be
ascribed to the excellent bioinert background generated from the
hPG layer.
The biomarker expression level of different cancer cell lines
greatly determines the cell-interface binding affinity.[46] To ex-
plore the specificity of these nanostructured biointerfaces for can-
cer cell capture, three kinds of cell lines, that is, MCF7 and T47D
(high EpCAM expression), MDA-MB-231 and A549 (low EpCAM
expression), GFP+-HeLa (EpCAM-negative cells), were spiked
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Figure 3. High performance of CTCs captures on antibody functionalized nanostructured mPG4 surfaces. a) Representative images of cells captured on
mPG4 surfaces with and without antibody conjugation. MCF7 (EpCAM positive) cells are pre-stained with CellTrace yellow dye. The scale bar indicates
100 µm. b) Cells captured on smooth mPG0 surface (anti-EpCAM conjugated hPG monolayer coating on smooth glass slides) and nanostructured mPG4
surfaces (n = 20–25, 3 technical replicates). * indicates a statistically significant comparison with P < 0.05 (one-way ANOVA). c) Time dependence cell
capture on antibody functionalized smooth mPG0 surface and nanostructured mPG4 surfaces. d) Cell capture efficiency on anti-EpCAM-mPG4 surfaces
for different cell lines with anti-EpCAM-mPG0 surfaces as control (n = 15–20, 3 technical replicates). e) Biospecific cancer cell capture on anti-EpCAM-
mPG4 surfaces from MCF7 spiked RBC lysed blood samples and whole blood samples (n = 20–25, 3 technical replicates). The spiked cell concentration
is 2000 cells mL−1. f) Fluorescent micrographs of captured cells on anti-EpCAM-mPG4 surfaces from artificial patient blood samples stained for the
nucleus (DAPA, blue), actin (phalloidin, yellow), epithelial marker cytokeratin 18 (CK-18, green), leukocyte marker (CD45, red). The scale bar indicates
5 µm. g) Representative immunofluorescence images of captured cells on the mPG4 surface without anti-body conjugation and anti-EpCAM-mPG4
surfaces from artificial patient blood samples. The scale bar indicates 20 µm. h) Linear correlation between the number of spiked and captured cells on
anti-EpCAM-mPG4 surfaces from artificial patient blood samples (n = 3 for each condition). The inset indicates the capture performance for ultra-low
concentrations of cancer cells (2, 5, 10, 20, and 50 cells mL−1 of lysed blood, n = 6).
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into serum-free medium and incubated with anti-EpCAM func-
tionalized mPG4 surfaces for 1 h, respectively. Similar to MCF7
cells, high EpCAM expression T47D displayed a higher affinity
to the biofunctionalized surfaces and more than 88% of spiked
cells were specifically captured onto anti-EpCAM-mPG4 surfaces
(Figure 3d). Even the MDA-MB-231 and A549 cells have a lower
EpCAM expression on the cell membrane, there are still ≈75%
of MDA-MB-231 cells and ≈80% of A549 cells were successively
isolated by these biointerfaces. In contrast, the antibody func-
tionalized mPG4 surfaces exhibited a very low capture efficiency
for EpCAM-negative HeLa cells (<5%), which may be nonspecif-
ically trapped on surfaces (Figure 3d). It needs to notice that the
capture efficiency for both high- and low-EpCAM expression can-
cer cells were remarkably enhanced by the surficial nanostruc-
tured features, especially for the cell lines with lower EpCAM
expression level. More than 5 times and 2 times capture effi-
ciency improvements were found on the anti-EpCAM function-
alized mPG4 surfaces compared to the smooth control surfaces
for A549 cancer cells and MDA-MB-231 cancer cells, respectively
(Figure 3d).
To further verify the potential application of this nanostruc-
tured biointerface in cancer diagnosis, we then spiked the cancer
cells into human blood and obtained artificial cancer patient’s
blood samples. As shown in Figure 3e, roughly 90% of MCF7
cancer cells were captured from lysed blood and ≈72% were cap-
tured from the whole blood sample by the nanostructured bioin-
terface (anti-EpCAM-mPG4) after 1-h incubation. Immunostain-
ing was used to distinguish the captured cancer cells from blood
cells on nanostructured surfaces. Captured cells were identified
as CTC cells when they were immunostained positive for anti-
CK18 (a protein marker for epithelial cells) but negative for anti-
CD45 (CD45, a marker for leukocytes) (Figure 3f). Compared
with nanostructured surfaces without antifouling background
and specific biomarker (mPG4 surfaces), the anti-EpCAM-mPG4
nanostructured surfaces displayed a high biospecificity for MCF7
cancer cells (CK18+/CD45-/DAPI+) and excellent resistance to
the adhesion of leukocytes (CK18-/CD45+/DAPI+) (Figure 3g).
The resulting capture purity for anti-EpCAM-mPG4 nanostruc-
tured surfaces was 93 ± 2.8% (Figure S7, Supporting Informa-
tion). It is known that the abundance of CTCs in patient blood
samples is very rare and ranges from a few to hundreds per
milliliter.[47] Thus, to explore the detection sensitivity of these
nanostructured biointerfaces, we further spiked the MCF7 can-
cer cells into lysed whole blood with a concentration from 2000
to 2 cells mL−1. As shown in Figure 3h, a nice linear correlation
between the number of spiked cells and captured cells was ob-
served. These biospecific nanostructured interfaces can still effi-
ciently capture the CTCs from a very dilute suspension, that is,
≈2 cells mL−1 (capture efficiency >75%).
2.4. Nanostructured Topographic Features Enhance Antibody
Conjugation and Cancer Cell Adhesion
To explore the underlying mechanism responding for the high
cancer cell capture performance on nanostructured surfaces, im-
munochemistry was first performed to quantify the density of
conjugated antibody on topographic surfaces with different sur-
face roughness. As shown in Figure 4a, the antibody conjugation
on the coating surface was progressively increasing with the in-
crease of surface roughness, which provides more surface area
for biomarkers immobilization. Then the detailed morphology
of the captured cells on nanostructured surfaces with different
roughness was observed by scanning electron microscope (Fig-
ure 4b). This indicates that the cancer cells prefer to spread on
surfaces with lower roughness and maintained a round mor-
phology. While the spreading of the cell on nanostructured sur-
faces slightly decrease but more protruding with the increase of
surface roughness. Filopodia are actin-rich plasma-membrane
protrusions and function as antennae for cells to probe their
environment,[48] which play an important role in cell-interface
interaction during cell adhesion and spreading. The length of
the filopodia of the adhered cells on nanostructured surfaces was
then quantified. Only a few and short filopodia were observed
from cells on the surface with lower roughness (Figure 4b,c). But
the filopodia formation on nanostructured surfaces was gradu-
ally enhanced with the increase of surface roughness and max-
imized at mPG4 surfaces. Thereafter, the increased roughness
largely restricted the expression of filopodia on nanostructured
surfaces. It means the topographical features would strengthen
cell-biointerface interaction if their size were in a suitable range,
that is, <350 nm for MCF7 cells. The further increased surface
roughness possibly limits cell extension in the horizontal direc-
tion and the cells adapt themselves to minimize their contact with
those surficial features.[3] Accordingly, cell membrane mobility
and filopodia formation are hindered during cell adhesion.[32]
Thus, this roughness selective manner of cell-interface interac-
tions explains the roughness-dependent capture efficiency of can-
cer cells on nanostructured surfaces. It also demonstrates that
the enhancement effect of surficial topographical features on cell
capture should be in a preferred range according to the size of
cells.[19,26]
Cell sense and respond to substrate topography through
integrin-mediated mechanotransduction. Paxillin in adhesion
complexes was stained to examine the effect of topographical fea-
tures on FAs formation. As shown in Figure 4d, clear punctate
structures and mature FAs in cells on mPG4 surfaces were ob-
served, while no obvious punctate structures and FAs were found
on the mPG1 surface with lower roughness (Rq = 56 nm) and
the mPG24 surface with higher roughness (Rq = 572 nm). The
molecular arrangement of integrin-mediated FAs formation is
sensitive to the surficial nanostructured features but should be
in a suitable range, and hence possibly results in distinct adhe-
sion behaviors.
Overall, the nanostructure features on biointerfaces could
greatly increase the surface area available for bioligands conjuga-
tion and the contact between nanoscale cell-surface components
and the nanofeatures on biointerfaces. Furthermore, the nanos-
tructures that mimic the nanoscale features found in the tissue
microenvironment could enhance the formation of filopodia and
FA, resulting in highly efficient affinity capture.
2.5. Reversible Release of Captured Cancer Cells Via Dynamic
Ligands Bonding
Benefiting from the dynamic cis-diols/PBA binding chemistry,
the competitive dissociation of conjugated bioligands facilitates
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Figure 4. The underlying mechanism for cancer cell capture on nanostructured surfaces with a surface roughness selective manner. a) Quantification of
the relative conjugated antibodies on nanostructured surfaces with different surface roughness (n = 4–5, 3 technical replicates). The antibody-conjugated
surfaces are immunofluorescence stained by Cy5-conjugated goat polyclonal secondary antibody to mouse IgG. b) Representative SEM images of ad-
hered cancer cells on nanostructured surfaces and c) the filopodia length of the adhered cancer cells on nanostructured surfaces (n = 10–15, 3 technical
replicates). * indicates a statistically significant comparison with P < 0.05 (one-way ANOVA). The scale bar indicates 10 µm. d) Representative fluores-
cence images of paxillin immunostaining cancer cells on mPG0, mPG4, and mPG24 surfaces, respectively. The scale bar indicates 10 µm.
the responsive detachment of captured cells from the nanostruc-
tured surfaces in the presence of higher affinity cis-diols to PBA,
that is, sorbitol[25,33] (Figure 5a). After adding the glycan into the
medium (0.1 M sorbitol), the spread cells on the nanostructured
surfaces gradually round-up (Figure 5b). Both the cell morphol-
ogy and adhesion status dramatically altered after 10 min incu-
bation at 37 °C. Almost all the captured cells were easily removed
by gently rinsing with PBS buffer after 20 min incubation (Fig-
ure 5b). This sugar-responsive cell detachment results from the
competitive unbinding of bioligands from basal surfaces. Thus,
cells cannot maintain adhesion onto antifouling surfaces any-
more in the absence of adhesive ligands and subsequently detach.
The sorbitol dose-dependent and incubation time-dependent re-
leasing efficiency were also investigated and shown in Figure 5c.
Although the detachment of cells under 0.1 M sorbitol solution
was comparably quicker than that under 0.05 M sorbitol solution
at the beginning, there was no significant difference in their re-
lease efficiency after 30 min incubation that 98 ± 1.5% of release
efficiency has already been achieved. In addition to the high de-
tachment efficiency, the integrity and viability of the released cells
are required and very important for downstream biological anal-
ysis. Thus, the released cells were re-cultured in a fresh medium
and the proliferation ability of released cells was quantified via
CCK8 assay (Figure 5d,e). Compared with the control group, the
released cells still kept high viability, and no significant difference
in the proliferation was observed between the control cells and
the released cells even using a higher concentration of sorbitol.
3. Conclusion
Overall, an advanced biointerface with well-defined topograph-
ical features was developed via a new generation of mussel-
inspired coating polymers. The adhesion of cancer cells on
these nanostructured biointerfaces was greatly enhanced com-
pared with smooth surfaces and exhibited an interesting bipha-
sic roughness-dependent manner. Under the presence of an
antifouling coating layer and conjugated biospecific ligands,
the generated biofunctional nanostructured surfaces exhibited a
high performance for specific cancer cell capture which results
from the improvement of bioligand conjugation, increase the
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Figure 5. Sorbitol-induced release of captured cancer cells on nanostructured surfaces. a) Schematic illustration of the mechanism of cancer cell release.
The sorbitol has a stronger affinity than the diols from hPG to PBA and results in the release of captured cells from the surface by competitive binding.
b) Representative microscopy images of cancer cell responsive release on anti-EpCAM-mPG4 surfaces. c) Incubation time and sorbitol concentration-
dependent release efficiency of cancer cells on anti-EpCAM-mPG4 surfaces. (n = 15–20, 3 technical replicates). d) The cell viability of released cancer
cells from anti-EpCAM-mPG4 surfaces by re-culturing and e) the proliferation analysis of the released cells by CCK-8 assay. The OD value at 450 nm
represents the activity of cancer cells. The scale bar indicates 100 µm.
cell-biointerface contact area, and enhancement of filopodia for-
mation and focal adhesion by the topographical features in an
optimized size. It should be highlighted that the hPG monolayer
on the biointerfaces herein not only provides an excellent bioin-
ert background but also enables directly bioligands conjugation
through the PBA-diols dynamic binding and subsequently de-
tach the bioligands via competitive glycan unbinding. Thus, the
resulting surfaces are able to biospecifically capture CTCs with
high efficiency (>95%) and purity (>96%) and “on-demand” re-
lease the captured cells quickly without damage. These results
provide a new strategy to regulate cancer cell adhesion/capture
via the biophysical cues and prospects for designing integrated
biointerfaces for advanced cell-based biomedical studies in the
future. Furthermore, the proposed method for in situ conjugat-
ing and dissociating bioligands onto the bioinert surface via the
responsive diols/PBA binding is not limited to the anti-EpCAM
for cancer cell isolation but also works for versatile homo/hetero-
bioligands immobilization once they have been modified with
PBA, which simplifies the multivalent and multifunctional bioin-
terfaces preparation.
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